Evidence map›Paper›PMID 41460714›Full record

ArticleStatistical methods in medical research2026

Robust Emax model fitting: Addressing nonignorable missing binary outcome in dose-response analysis.

Jiangshan Zhang, Vivek Pradhan, Yuxi Zhao

Abstract read
In one paragraph

Article in Statistical methods in medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jiangshan ZhangDepartment of Statistics, University of California, Davis, USA.ORCID 0009-0004-7716-238X
Vivek PradhanGlobal Biometrics and Data Management, Immunology and Inflammation, Pfizer Inc., USA.ORCID 0000-0003-4590-5383
Yuxi ZhaoGlobal Biometrics and Data Management, Immunology and Inflammation, Pfizer Inc., USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Binary Emax model is widely employed in dose-response analysis during drug development, where missing data often pose significant challenges. Addressing nonignorable missing binary responses-where the likelihood of missing data is related to unobserved outcomes-is particularly important, yet existing methods often lead to biased estimates. This issue is compounded when using the regulatory-recommended ''imputing as treatment failure'' approach, known as non-responder imputation (NRI). Moreover, the problem of separation, where a predictor perfectly distinguishes between outcome classes, can further complicate likelihood maximization. In this paper, we introduce a penalized likelihood-based method that integrates a modified expectation-maximization (EM) algorithm in the spirit of Ibrahim and Lipsitz to effectively manage both nonignorable missing data and separation issues. Our approach applies a noninformative Jeffreys' prior to the likelihood, reducing bias in parameter estimation. Simulation studies demonstrate that our method outperforms existing methods, such as NRI, and the superiority is further supported by its application to data from a Phase II clinical trial. Additionally, we have developed an R package,

Indexed as

Dose-Response Relationship, DrugModels, StatisticalAlgorithmsBiasClinical Trials, Phase II as TopicComputer SimulationData Interpretation, StatisticalHumansLikelihood FunctionsDose–responseEM algorithmEmax modelFirth correctionnoignorable missingseparation

Identifiers

PMID41460714
PMCPMC13036265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.